Compare UBER & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UBER | VRTX |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.5B | 123.4B |
| IPO Year | 2019 | 2006 |
| Metric | UBER | VRTX |
|---|---|---|
| Price | $71.91 | $479.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 33 | 29 |
| Target Price | $107.03 | ★ $539.69 |
| AVG Volume (30 Days) | ★ 15.4M | 1.4M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.73 | ★ 836.54 |
| EPS | 0.13 | ★ 4.02 |
| Revenue | ★ $52,017,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | $14.41 | $10.79 |
| Revenue Next Year | $14.29 | $10.47 |
| P/E Ratio | $550.85 | ★ $117.29 |
| Revenue Growth | 18.28 | ★ 46.20 |
| 52 Week Low | $65.41 | $362.50 |
| 52 Week High | $101.99 | $533.67 |
| Indicator | UBER | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.95 | 50.37 |
| Support Level | $68.44 | $467.30 |
| Resistance Level | $78.06 | $488.71 |
| Average True Range (ATR) | 2.04 | 12.67 |
| MACD | 0.10 | -1.84 |
| Stochastic Oscillator | 62.80 | 46.71 |
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars as well as autonomous vehicles, but could eventually be used for additional products and services, such as delivery via drones or electronic vehicle take-off and landing (eVTOL) technology. Uber operates in over 70 countries, with over 202 million users who order rides or food at least once a month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.